{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T09:13:36Z","timestamp":1790327616514,"version":"4.1.0"},"reference-count":133,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:00:00Z","timestamp":1590710400000},"content-version":"am","delay-in-days":363,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolism"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.diabet.2018.07.003","type":"journal-article","created":{"date-parts":[[2018,7,23]],"date-time":"2018-07-23T02:48:35Z","timestamp":1532314115000},"page":"238-247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"title":["Diabetes-related cardiomyopathy: The sweet story of glucose overload from epidemiology to cellular pathways"],"prefix":"10.1016","volume":"45","author":[{"given":"M.","family":"Joubert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Manrique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Cariou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Prieur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2018.07.003_bib0005","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(16)00618-8","article-title":"Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants","volume":"387","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2018.07.003_bib0010","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S2213-8587(14)70102-0","article-title":"Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment","volume":"2","author":"Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2018.07.003_bib0015","doi-asserted-by":"crossref","first-page":"149","DOI":"10.7326\/0003-4819-147-3-200708070-00167","article-title":"Mortality trends in men and women with diabetes, 1971 to 2000","volume":"147","author":"Gregg","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabet.2018.07.003_bib0020","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/jhh.2009.43","article-title":"The diabetic, hypertensive heart: epidemiology and mechanisms of a very high-risk situation","volume":"23","author":"Franjic","year":"2009","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.diabet.2018.07.003_bib0025","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.2337\/diacare.27.8.1879","article-title":"The incidence of congestive heart failure in type 2 diabetes: an update","volume":"27","author":"Nichols","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2018.07.003_bib0030","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1007\/s00125-016-3971-y","article-title":"Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006\u20132013","volume":"59","author":"Norhammar","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2018.07.003_bib0035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/ehf2.12195","article-title":"In-hospital worsening heart failure: a clinically relevant endpoint?","volume":"5","author":"Clark","year":"2018","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.diabet.2018.07.003_bib0040","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.2337\/diacare.24.9.1614","article-title":"Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors","volume":"24","author":"Nichols","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2018.07.003_bib0045","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1161\/CIRCULATIONAHA.116.022194","article-title":"Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus\u00a0\u2014\u00a0Mechanisms, management, and clinical considerations","volume":"133","author":"Low Wang","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2018.07.003_bib0050","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/0002-9149(72)90595-4","article-title":"New type of cardiomyopathy associated with diabetic glomerulosclerosis","volume":"30","author":"Rubler","year":"1972","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.diabet.2018.07.003_bib0055","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1172\/JCI108843","article-title":"Evidence for cardiomyopathy in familial diabetes mellitus","volume":"60","author":"Regan","year":"1977","journal-title":"J Clin Invest"},{"key":"10.1016\/j.diabet.2018.07.003_bib0060","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1161\/01.CIR.82.3.848","article-title":"A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease","volume":"82","author":"van Hoeven","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2018.07.003_bib0065","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1161\/CIRCULATIONAHA.106.621854","article-title":"Advanced glycation end products: sparking the development of diabetic vascular injury","volume":"114","author":"Goldin","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2018.07.003_bib0070","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/0002-8703(80)90379-8","article-title":"Clinical and morphological features of human hypertensive-diabetic cardiomyopathy","volume":"99","author":"Factor","year":"1980","journal-title":"Am Heart J"},{"key":"10.1016\/j.diabet.2018.07.003_bib0075","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0046-8177(84)80307-X","article-title":"Pathomorphologic aspects of muscular tissue in diabetes mellitus","volume":"15","author":"Fischer","year":"1984","journal-title":"Hum Pathol"},{"key":"10.1016\/j.diabet.2018.07.003_bib0080","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1093\/eurheartj\/ehv134","article-title":"Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes","volume":"36","author":"Seferovi\u0107","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabet.2018.07.003_bib0085","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1093\/eurheartj\/ehm037","article-title":"How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology","volume":"28","author":"Paulus","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabet.2018.07.003_bib0090","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s11897-015-0261-9","article-title":"Role of imaging techniques for diagnosis, prognosis and management of heart failure patients: cardiac magnetic resonance","volume":"12","author":"Gonzalez","year":"2015","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.diabet.2018.07.003_bib0095","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/ehjci\/jeu121","article-title":"Subclinical diastolic dysfunction in young adults with Type 2 diabetes mellitus: a multiparametric contrast-enhanced cardiovascular magnetic resonance pilot study assessing potential mechanisms","volume":"15","author":"Khan","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.diabet.2018.07.003_bib0100","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.289.2.194","article-title":"Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic","volume":"289","author":"Redfield","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.diabet.2018.07.003_bib0105","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jacc.2005.02.093","article-title":"Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure","volume":"46","author":"Doehner","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabet.2018.07.003_bib0110","doi-asserted-by":"crossref","first-page":"671","DOI":"10.2337\/dc16-2016","article-title":"ESC-HFA heart failure long-term registry, association between diabetes and 1-year adverse clinical outcomes in a multinational cohort of ambulatory patients with chronic heart failure: results from the ESC-HFA heart failure long-term registry","volume":"40","author":"Dauriz","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2018.07.003_bib0115","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.amjcard.2017.03.005","article-title":"Comparison of predictors of heart failure ith preserved versus reduced ejection fraction in a multiracial cohort of preclinical left ventricular diastolic dysfunction","volume":"119","author":"Zhang","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.diabet.2018.07.003_bib0120","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12933-017-0582-y","article-title":"Admission blood glucose and 10-year mortality among patients with or without pre-existing diabetes mellitus hospitalized with heart failure","volume":"16","author":"Itzhaki Ben Zadok","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabet.2018.07.003_bib0125","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2337\/diacare.27.3.699","article-title":"Heart failure prevalence, incidence, and mortality in the elderly with diabetes","volume":"27","author":"Bertoni","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2018.07.003_bib0130","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/eurheartj\/ehn153","article-title":"Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: assessment of reduction in mortality and morbidity (CHARM) programme","volume":"29","author":"MacDonald","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabet.2018.07.003_bib0135","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1136\/heartjnl-2014-307391","article-title":"Subclinical LV dysfunction and 10-year outcomes in type 2 diabetes mellitus","volume":"101","author":"Holland","year":"2015","journal-title":"Heart"},{"key":"10.1016\/j.diabet.2018.07.003_bib0140","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1161\/01.CIR.103.22.2668","article-title":"Glycemic control and heart failure among adult patients with diabetes","volume":"103","author":"Iribarren","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2018.07.003_bib0145","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/eurjhf\/hfs156","article-title":"Association between glycated haemoglobin and the risk of congestive heart failure in diabetes mellitus: systematic review and meta-analysis","volume":"15","author":"Erqou","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.diabet.2018.07.003_bib0150","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004409","article-title":"Prognostic value of N-terminal Pro-B-type natriuretic peptide levels in heart failure patients with and without atrial fibrillation","volume":"10","author":"Kristensen","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.diabet.2018.07.003_bib0155","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2018.07.003_bib0160","doi-asserted-by":"crossref","first-page":"C794","DOI":"10.1152\/ajpcell.00251.2013","article-title":"Role for high-glucose-induced protein O-GlcNAcylation in stimulating cardiac fibroblast collagen synthesis","volume":"306","author":"Aguilar","year":"2014","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.diabet.2018.07.003_bib0165","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/ejhf.455","article-title":"Mean HbA1c and mortality in diabetic individuals with heart failure: a population cohort study","volume":"18","author":"Elder","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.diabet.2018.07.003_bib0170","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2337\/dc08-1775","article-title":"Lipid and lipoprotein profiles in youth with and without type 1 diabetes: the SEARCH for diabetes in youth case-control study","volume":"32","author":"Guy","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2018.07.003_bib0175","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1111\/dom.12973","article-title":"Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes","volume":"19","author":"Cusi","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2018.07.003_bib0180","doi-asserted-by":"crossref","first-page":"R225","DOI":"10.1530\/JME-16-0249","article-title":"Lipid metabolism and its implications for type 1 diabetes-associated cardiomyopathy","volume":"58","author":"Ritchie","year":"2017","journal-title":"J Mol Endocrinol"},{"key":"10.1016\/j.diabet.2018.07.003_bib0185","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S2213-8587(15)00292-2","article-title":"Long-term excess risk of heart failure in people with type 1 diabetes: a prospective case-control study","volume":"3","author":"Rosengren","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2018.07.003_bib0190","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2337\/diacare.17.7.633","article-title":"Which left ventricular function is impaired earlier in the evolution of diabetic cardiomyopathy? An echocardiographic study of young type I diabetic patients","volume":"17","author":"Raev","year":"1994","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2018.07.003_bib0195","doi-asserted-by":"crossref","first-page":"57","DOI":"10.5507\/bp.2003.008","article-title":"Left ventricular diastolic filling in young persons with type 1 diabetes mellitus","volume":"147","author":"Berkov\u00e1","year":"2003","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"10.1016\/j.diabet.2018.07.003_bib0200","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.diabet.2014.03.007","article-title":"Longitudinal left ventricular strain impairment in type 1 diabetes children and adolescents: a 2D speckle strain imaging study","volume":"40","author":"Labombarda","year":"2014","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabet.2018.07.003_bib0205","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.2337\/diacare.23.12.1804","article-title":"Reversal of left ventricular diastolic dysfunction after kidney-pancreas transplantation in type 1 diabetic uremic patients","volume":"23","author":"Fiorina","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2018.07.003_bib0210","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/eht193","article-title":"Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission","volume":"35","author":"Wong","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabet.2018.07.003_bib0215","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0002-9149(02)02381-0","article-title":"Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy","volume":"90","author":"Grothues","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.diabet.2018.07.003_bib0220","doi-asserted-by":"crossref","first-page":"6698","DOI":"10.1038\/s41598-017-07083-1","article-title":"Test-retest reproducibility of cardiac magnetic resonance imaging in healthy mice at 7-Tesla: effect of anesthetic procedures","volume":"7","author":"Joubert","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.diabet.2018.07.003_bib0225","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12933-017-0651-2","article-title":"Increased myocardial extracellular volume assessed by cardiovascular magnetic resonance T1 mapping and its determinants in type 2 diabetes mellitus patients with normal myocardial systolic strain","volume":"17","author":"Cao","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabet.2018.07.003_bib0230","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2337\/diacare.24.1.5","article-title":"Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of manoeuvres in echocardiographic screening for preclinical diabetic cardiomyopathy","volume":"24","author":"Poirier","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2018.07.003_bib0235","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.amjcard.2003.12.026","article-title":"Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus","volume":"93","author":"Boyer","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.diabet.2018.07.003_bib0240","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.jacc.2017.07.792","article-title":"Clinical implications of echocardiographic phenotypes of patients with diabetes mellitus","volume":"70","author":"Ernande","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabet.2018.07.003_bib0245","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.echo.2014.01.001","article-title":"Longitudinal myocardial strain alteration is associated with left ventricular remodeling in asymptomatic patients with type 2 diabetes mellitus","volume":"27","author":"Ernande","year":"2014","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.diabet.2018.07.003_bib0250","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12933-016-0333-5","article-title":"Incremental prognostic value of global longitudinal strain in patients with type 2 diabetes mellitus","volume":"15","author":"Liu","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabet.2018.07.003_bib0255","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1210\/jc.2017-00954","article-title":"HbA1c identifies subjects with prediabetes and subclinical left ventricular diastolic dysfunction","volume":"102","author":"Di Pino","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2018.07.003_bib0260","doi-asserted-by":"crossref","first-page":"e003643","DOI":"10.1161\/CIRCIMAGING.115.003643","article-title":"Impact of improved glycemic control on cardiac function in type 2 diabetes mellitus","volume":"9","author":"Leung","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.diabet.2018.07.003_bib0265","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jacc.2009.04.074","article-title":"Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging","volume":"54","author":"Rijzewijk","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabet.2018.07.003_bib0270","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.bbalip.2016.03.014","article-title":"Fuel availability and fate in cardiac metabolism: a tale of two substrates","volume":"1861","author":"Pascual","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.diabet.2018.07.003_bib0275","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/cvr\/cvn093","article-title":"Insulin signalling in the heart","volume":"79","author":"Bertrand","year":"2008","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.diabet.2018.07.003_bib0280","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.2337\/diabetes.53.9.2366","article-title":"Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob\/ob mouse hearts","volume":"53","author":"Mazumder","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2018.07.003_bib0285","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1161\/01.CIR.0000012466.50373.E8","article-title":"Adaptation and maladaptation of the heart in diabetes: part I: general concepts","volume":"105","author":"Taegtmeyer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2018.07.003_bib0290","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1161\/01.CIR.0000012467.61045.87","article-title":"Adaptation and maladaptation of the heart in diabetes: part II: potential mechanisms","volume":"105","author":"Young","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2018.07.003_bib0295","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0022-2828(08)80016-8","article-title":"Myocardial substrate metabolism: implications for diabetic cardiomyopathy","volume":"27","author":"Rodrigues","year":"1995","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.diabet.2018.07.003_bib0300","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.2337\/db08-0079","article-title":"Type 1 diabetic akita mouse hearts are insulin sensitive but manifest structurally abnormal mitochondria that remain coupled despite increased uncoupling protein 3","volume":"57","author":"Bugger","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2018.07.003_bib0305","doi-asserted-by":"crossref","first-page":"H1763","DOI":"10.1152\/ajpheart.01063.2005","article-title":"Perfused hearts from Type 2 diabetic (db\/db) mice show metabolic responsiveness to insulin","volume":"290","author":"Hafstad","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.diabet.2018.07.003_bib0310","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.2967\/jnumed.108.051672","article-title":"Time course of alterations in myocardial glucose utilization in the Zucker diabetic fatty rat with correlation to gene expression of glucose transporters: a small-animal PET investigation","volume":"49","author":"Shoghi","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diabet.2018.07.003_bib0315","first-page":"689","article-title":"Assessment of myocardial metabolism in diabetic rats using small-animal PET: a feasibility study","volume":"47","author":"Welch","year":"2006","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diabet.2018.07.003_bib0320","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1475-2840-8-39","article-title":"Altered myocardial substrate metabolism is associated with myocardial dysfunction in early diabetic cardiomyopathy in rats: studies using positron emission tomography","volume":"8","author":"van den Brom","year":"2009","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabet.2018.07.003_bib0325","doi-asserted-by":"crossref","first-page":"E1049","DOI":"10.1152\/ajpendo.00560.2009","article-title":"Abnormal in vivo myocardial energy substrate uptake in diet-induced type 2 diabetic cardiomyopathy in rats","volume":"298","author":"M\u00e9nard","year":"2010","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.diabet.2018.07.003_bib0330","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1210\/en.2012-2272","article-title":"High-fat feeding-induced hyperinsulinemia increases cardiac glucose uptake and mitochondrial function despite peripheral insulin resistance","volume":"154","author":"Gupte","year":"2013","journal-title":"Endocrinology"},{"key":"10.1016\/j.diabet.2018.07.003_bib0335","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.2337\/db16-0733","article-title":"The SGLT2 Inhibitor dapagliflozin prevents cardiomyopathy in a diabetic lipodystrophic mouse model","volume":"66","author":"Joubert","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2018.07.003_bib0340","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.2967\/jnumed.112.110114","article-title":"Repeatable non-invasive measurement of mouse myocardial glucose uptake with 18F-FDG: evaluation of tracer kinetics in a type 1 diabetes model","volume":"54","author":"Thorn","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diabet.2018.07.003_bib0345","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/BF03027431","article-title":"Evaluation of the relationship between physiological FDG uptake in the heart and age, blood glucose level, fasting period, and hospitalization","volume":"20","author":"Kaneta","year":"2006","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.diabet.2018.07.003_bib0350","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0008-6363(02)00399-1","article-title":"Cardiac carbohydrate metabolism in Zucker diabetic fatty rats","volume":"55","author":"Chatham","year":"2002","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.diabet.2018.07.003_bib0355","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.2337\/db14-1560","article-title":"Increasing pyruvate dehydrogenase flux as a treatment for diabetic cardiomyopathy: a combined 13C hyperpolarized magnetic resonance and echocardiography study","volume":"64","author":"Le Page","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2018.07.003_bib0360","doi-asserted-by":"crossref","first-page":"H1693","DOI":"10.1152\/ajpheart.00854.2012","article-title":"Insulin resistance protects the heart from fuel overload in dysregulated metabolic states","volume":"305","author":"Taegtmeyer","year":"2013","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.diabet.2018.07.003_bib0365","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1161\/CIRCULATIONAHA.113.008476","article-title":"Myocardial contractile dysfunction is associated with impaired mitochondrial function and dynamics in type 2 diabetic but not in obese patients","volume":"130","author":"Montaigne","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2018.07.003_bib0370","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.2337\/db16-0733","article-title":"The sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents cardiomyopathy in a diabetic lipodystrophic mouse model","volume":"66","author":"Joubert","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2018.07.003_bib0375","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12933-016-0489-z","article-title":"Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes","volume":"16","author":"Habibi","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabet.2018.07.003_bib0380","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.2337\/diabetes.51.6.1938","article-title":"Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway","volume":"51","author":"Cai","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2018.07.003_bib0385","doi-asserted-by":"crossref","first-page":"e004796","DOI":"10.1161\/JAHA.113.004796","article-title":"Glucose regulation of load-induced mTOR signaling and ER stress in mammalian heart","volume":"2","author":"Sen","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.diabet.2018.07.003_bib0390","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1210\/jc.2005-1904","article-title":"High glucose alters cardiomyocyte contacts and inhibits myofibrillar formation","volume":"91","author":"Dyntar","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diabet.2018.07.003_bib0395","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1161\/CIRCRESAHA.110.223545","article-title":"Oxidative stress and diabetic complications","volume":"107","author":"Giacco","year":"2010","journal-title":"Circ Res"},{"key":"10.1016\/j.diabet.2018.07.003_bib0400","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.yjmcc.2004.07.008","article-title":"Antioxidant treatment attenuates hyperglycemia-induced cardiomyocyte death in rats","volume":"37","author":"Fiordaliso","year":"2004","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.diabet.2018.07.003_bib0405","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1161\/hc4901.100382","article-title":"Impaired endothelial regulation of ventricular relaxation in cardiac hypertrophy: role of reactive oxygen species and NADPH oxidase","volume":"104","author":"MacCarthy","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2018.07.003_bib0410","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1161\/01.CIR.0000145160.04084.AC","article-title":"Role of myocardial neuronal nitric oxide synthase-derived nitric oxide in beta-adrenergic hyporesponsiveness after myocardial infarction-induced heart failure in rat","volume":"110","author":"Bendall","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2018.07.003_bib0415","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1016\/S0735-1097(03)00471-6","article-title":"Increased myocardial NADPH oxidase activity in human heart failure","volume":"41","author":"Heymes","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabet.2018.07.003_bib0420","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/cvr\/cvr071","article-title":"Glucose metabolism and cardiac hypertrophy","volume":"90","author":"Kolwicz","year":"2011","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.diabet.2018.07.003_bib0425","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1007\/s00125-006-0229-0","article-title":"Cardiac contractile dysfunction in Lep\/Lep obesity is accompanied by NADPH oxidase activation, oxidative modification of sarco(endo)plasmic reticulum Ca2+-ATPase and myosin heavy chain isozyme switch","volume":"49","author":"Li","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2018.07.003_bib0430","doi-asserted-by":"crossref","first-page":"H153","DOI":"10.1152\/ajpheart.01142.2008","article-title":"Superoxide production by NAD(P)H oxidase and mitochondria is increased in genetically obese and hyperglycemic rat heart and aorta before the development of cardiac dysfunction. The role of glucose-6-phosphate dehydrogenase-derived NADPH","volume":"297","author":"Serpillon","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.diabet.2018.07.003_bib0435","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/cvr\/cvp189","article-title":"Calpain activation contributes to hyperglycaemia-induced apoptosis in cardiomyocytes","volume":"84","author":"Li","year":"2009","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.diabet.2018.07.003_bib0440","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/cvr\/cvr230","article-title":"NADPH oxidase activation by hyperglycaemia in cardiomyocytes is independent of glucose metabolism but requires SGLT1","volume":"92","author":"Balteau","year":"2011","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.diabet.2018.07.003_bib0445","doi-asserted-by":"crossref","first-page":"41166","DOI":"10.1038\/srep41166","article-title":"Sodium-myoinositol cotransporter-1, SMIT1, mediates the production of reactive oxygen species induced by hyperglycemia in the heart","volume":"8","author":"Van Steenbergen","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.diabet.2018.07.003_bib0450","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1161\/CIRCRESAHA.116.306923","article-title":"Molecular and cellular mechanisms of cardiovascular disorders in diabetes","volume":"118","author":"Shah","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.diabet.2018.07.003_bib0455","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1111\/j.1582-4934.2008.00547.x","article-title":"Advanced glycation end-product (AGE) accumulation and AGE receptor (RAGE) up-regulation contribute to the onset of diabetic cardiomyopathy","volume":"13","author":"Ma","year":"2009","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.diabet.2018.07.003_bib0460","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1124\/mol.112.078352","article-title":"Carbonylation induces heterogeneity in cardiac ryanodine receptor function in diabetes mellitus","volume":"82","author":"Shao","year":"2012","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.diabet.2018.07.003_bib0465","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10741-013-9384-9","article-title":"Reactive carbonyl species and their roles in sarcoplasmic reticulum Ca2+ cycling defect in the diabetic heart","volume":"19","author":"Tian","year":"2014","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.diabet.2018.07.003_bib0470","doi-asserted-by":"crossref","first-page":"44230","DOI":"10.1074\/jbc.M303810200","article-title":"Diabetes and the accompanying hyperglycemia impairs cardiomyocyte calcium cycling through increased nuclear O-GlcNAcylation","volume":"278","author":"Clark","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.diabet.2018.07.003_bib0475","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1161\/01.RES.0000165478.06813.58","article-title":"Adenovirus-mediated overexpression of O-GlcNAcase improves contractile function in the diabetic heart","volume":"96","author":"Hu","year":"2005","journal-title":"Circ Res"},{"key":"10.1016\/j.diabet.2018.07.003_bib0480","doi-asserted-by":"crossref","first-page":"R689","DOI":"10.1152\/ajpregu.00548.2011","article-title":"Excess protein O-GlcNAcylation and the progression of diabetic cardiomyopathy","volume":"303","author":"Fricovsky","year":"2012","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.diabet.2018.07.003_bib0485","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1093\/glycob\/cwq071","article-title":"Inhibition of phospholamban phosphorylation by O-GlcNAcylation: implications for diabetic cardiomyopathy","volume":"20","author":"Yokoe","year":"2010","journal-title":"Glycobiology"},{"key":"10.1016\/j.diabet.2018.07.003_bib0490","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/nature12537","article-title":"Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation","volume":"502","author":"Erickson","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.diabet.2018.07.003_bib0495","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.2337\/db14-1107","article-title":"Removal of abnormal myofilament O-GlcNAcylation restores Ca2+ sensitivity in diabetic cardiac muscle","volume":"64","author":"Ramirez-Correa","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.diabet.2018.07.003_bib0500","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1074\/jbc.M808518200","article-title":"Increased enzymatic O-GlcNAcylation of mitochondrial proteins impairs mitochondrial function in cardiac myocytes exposed to high glucose","volume":"284","author":"Hu","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.diabet.2018.07.003_bib0505","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1073\/pnas.1424017112","article-title":"Diabetes-associated dysregulation of O-GlcNAcylation in rat cardiac mitochondria","volume":"112","author":"Banerjee","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.diabet.2018.07.003_bib0510","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00726-010-0699-8","article-title":"Activation of the hexosamine biosynthesis pathway and protein O-GlcNAcylation modulate hypertrophic and cell signaling pathways in cardiomyocytes from diabetic mice","volume":"40","author":"Marsh","year":"2011","journal-title":"Amino Acids"},{"key":"10.1016\/j.diabet.2018.07.003_bib0515","doi-asserted-by":"crossref","first-page":"H2122","DOI":"10.1152\/ajpheart.00775.2011","article-title":"GlcNAc signaling is essential for NFAT-mediated transcriptional reprogramming during cardiomyocyte hypertrophy","volume":"302","author":"Facundo","year":"2012","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.diabet.2018.07.003_bib0520","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1365-2796.2003.01271.x","article-title":"Metformin and lactic acidosis: cause or coincidence? A review of case reports","volume":"255","author":"Stades","year":"2004","journal-title":"J Intern Med"},{"key":"10.1016\/j.diabet.2018.07.003_bib0525","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1161\/CIRCHEARTFAILURE.112.000162","article-title":"Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients","volume":"6","author":"Eurich","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.diabet.2018.07.003_bib0530","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2165\/11596950-000000000-00000","article-title":"Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008","volume":"35","author":"Ruiter","year":"2012","journal-title":"Drug Saf"},{"key":"10.1016\/j.diabet.2018.07.003_bib0535","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/S0140-6736(14)61402-1","article-title":"Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy","volume":"385","author":"Gilbert","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2018.07.003_bib0540","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/eurheartj\/ehp604","article-title":"Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial","volume":"31","author":"Komajda","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabet.2018.07.003_bib0545","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.118.034763","article-title":"Heart failure after ischemic stroke or TIA in insulin-resistant patients without diabetes treated with pioglitazone","author":"Young","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2018.07.003_bib0550","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2018.07.003_bib0555","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2018.07.003_bib0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2011.07.030","article-title":"Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis","volume":"162","author":"Castagno","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.diabet.2018.07.003_bib0565","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/dom.13033","article-title":"Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes: a perspective on glucose-lowering interventions","volume":"20","author":"Roussel","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2018.07.003_bib0570","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2018.07.003_bib0575","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2018.07.003_bib0580","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2018.07.003_bib0585","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2018.07.003_bib0590","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2018.07.003_bib0595","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2018.07.003_bib0600","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia","volume":"367","author":"Gerstein","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2018.07.003_bib0605","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2018.07.003_bib0610","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2018.07.003_bib0615","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ejhf.657","article-title":"Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)\u2014A multicentre, double-blind, randomised, placebo-controlled trial","volume":"19","author":"Jorsal","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.diabet.2018.07.003_bib0620","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"316","author":"Margulies","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.diabet.2018.07.003_bib0625","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ahj.2017.10.003","article-title":"Effect of adding GLP-1RA on mortality, cardiovascular events, and metabolic outcomes among insulin-treated patients with type 2 diabetes: a large retrospective UK cohort study","volume":"196","author":"Anyanwagu","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.diabet.2018.07.003_bib0630","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","volume":"136","author":"Kosiborod","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2018.07.003_bib0635","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.117.030012","article-title":"Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials","volume":"136","author":"Lytvyn","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2018.07.003_bib0640","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2018.07.003_bib0645","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV protection in the EMPA-REG OUTCOME trial: a \u201cthrifty substrate\u201d hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2018.07.003_bib0650","doi-asserted-by":"crossref","first-page":"F77","DOI":"10.1152\/ajprenal.00555.2014","article-title":"Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus","volume":"308","author":"Lytvyn","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.diabet.2018.07.003_bib0655","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2018.07.003_bib0660","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11936-017-0522-x","article-title":"Promise of SGLT2 inhibitors in heart failure: diabetes and beyond","volume":"19","author":"Martens","year":"2017","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1016\/j.diabet.2018.07.003_bib0665","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"}],"container-title":["Diabetes & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363618301241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363618301241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:55:47Z","timestamp":1761130547000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363618301241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":133,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S1262363618301241"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2018.07.003","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diabetes-related cardiomyopathy: The sweet story of glucose overload from epidemiology to cellular pathways","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2018.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}